Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HU-F-AIM - A Prospective, Interventional Study to Evaluate HU-resistance in Polycythemia Vera Patients Who Meet Predictive Parameters Identified in the Machine Learning Project PV-AIM

NCT05853458 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05853458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05853458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HU-F-AIM - A Prospective, Interventional Study to Evaluate HU-resistance in Polycythemia Vera Patients Who Meet Predictive Parameters Identified in the Machine Learning Project PV-AIM
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Terminated
Start date
July 28, 2023
Completion date
February 26, 2026
Enrollment
76 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera